For the quarter ended June 2026, Halozyme Therapeutics (HALO) reported revenue of $481 million, up 47.7% over the same period last year. EPS came in at $2.28, compared to $1.54 in the year-ago quarter.

The reported revenue represents a surprise of +17.44% over the Zacks Consensus Estimate of $409.57 million. With the consensus EPS estimate being $1.82, the EPS surprise was +25.28%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Halozyme Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- Product sales, net: $129.63 million compared to the $110.4 million average estimate based on four analysts. The reported number represents a change of +59% year over year.
  • Revenues- Royalties: $307.7 million versus $274.03 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +49.6% change.
  • Revenues- Revenues under collaboration agreements: $43.67 million versus the four-analyst average estimate of $25.14 million. The reported number represents a year-over-year change of +13.2%.

View all Key Company Metrics for Halozyme Therapeutics here>>>

Shares of Halozyme Therapeutics have returned +4% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

See them now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research